TP53 chromothripsis chronic lymphocytic leukemia genomic complexity genomic microarrays optical genome mapping

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 Jul 2022
Historique:
received: 14 06 2022
revised: 22 07 2022
accepted: 27 07 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 13 8 2022
Statut: epublish

Résumé

Chromothripsis (cth) has been associated with a dismal outcome and poor prognosis factors in patients with chronic lymphocytic leukemia (CLL). Despite being correlated with high genome instability, previous studies have not assessed the role of cth in the context of genomic complexity. Herein, we analyzed a cohort of 33 CLL patients with cth and compared them against a cohort of 129 non-cth cases with complex karyotypes. Nine cth cases were analyzed using optical genome mapping (OGM). Patterns detected by genomic microarrays were compared and the prognostic value of cth was analyzed. Cth was distributed throughout the genome, with chromosomes 3, 6 and 13 being those most frequently affected. OGM detected 88.1% of the previously known copy number alterations and several additional cth-related rearrangements (median: 9, range: 3-26). Two patterns were identified: one with rearrangements clustered in the region with cth (3/9) and the other involving both chromothriptic and non-chromothriptic chromosomes (6/9). Cases with cth showed a shorter time to first treatment (TTFT) than non-cth patients (median TTFT: 2 m vs. 15 m;

Identifiants

pubmed: 35954380
pii: cancers14153715
doi: 10.3390/cancers14153715
pmc: PMC9367500
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Government of Catalonia
ID : 17SGR437
Organisme : Gilead Sciences (Spain)
ID : GLD17/00282
Organisme : Ministerio de Universidades (Spain)
ID : FPU17/00361

Références

Chin Med J (Engl). 2015 Apr 5;128(7):985-7
pubmed: 25836623
Haematologica. 2022 Mar 01;107(3):593-603
pubmed: 33691382
Leukemia. 2018 Feb;32(2):332-342
pubmed: 28584254
Cancer. 2015 Oct 15;121(20):3612-21
pubmed: 26193999
Blood. 2017 Jun 29;129(26):3495-3498
pubmed: 28446433
Leukemia. 2020 Nov;34(11):2887-2897
pubmed: 32651540
Haematologica. 2020 Jan 23;106(1):87-97
pubmed: 31974198
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
BMC Genomics. 2014 Jan 29;15:82
pubmed: 24476156
Leukemia. 2016 Nov;30(11):2179-2186
pubmed: 27282254
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Nature. 2015 Jun 11;522(7555):179-84
pubmed: 26017310
Mol Cytogenet. 2019 Feb 11;12:6
pubmed: 30805029
Cancer Cell. 2013 May 13;23(5):567-9
pubmed: 23680143
Cell. 2015 Dec 17;163(7):1641-54
pubmed: 26687355
Blood. 2017 Jun 22;129(25):3362-3370
pubmed: 28473407
Lancet Oncol. 2016 Feb;17(2):200-211
pubmed: 26655421
Blood. 2012 Dec 6;120(24):4783-94
pubmed: 23047824
Am J Hematol. 2017 Oct;92(10):E604-E607
pubmed: 28699185
Cancers (Basel). 2022 Jul 11;14(14):
pubmed: 35884436
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Leuk Res Rep. 2012 Jan 1;1(1):4-6
pubmed: 23930239
Genome Res. 2013 Feb;23(2):217-27
pubmed: 23132910
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
Nat Med. 2012 Nov;18(11):1630-8
pubmed: 23135524
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Haematologica. 2018 Sep;103(9):1511-1517
pubmed: 29880613
Blood. 2019 Mar 14;133(11):1205-1216
pubmed: 30602617
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Blood. 2016 Jul 21;128(3):395-404
pubmed: 27226433
Am J Hematol. 2022 May;97(5):548-561
pubmed: 35119131
J Clin Oncol. 2020 Dec 1;38(34):4042-4054
pubmed: 32986498
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Am J Hum Genet. 2021 Aug 5;108(8):1423-1435
pubmed: 34237281
Genes Chromosomes Cancer. 2022 Jan;61(1):37-43
pubmed: 34414624
Leukemia. 2018 Jan;32(1):83-91
pubmed: 28592889
N Engl J Med. 2016 Jan 28;374(4):323-32
pubmed: 26641137
Genes Chromosomes Cancer. 2015 Nov;54(11):668-80
pubmed: 26305789
Oncotarget. 2017 Apr 21;8(33):54297-54303
pubmed: 28903342
Cancer Genet. 2018 Dec;228-229:236-250
pubmed: 30554732
Blood. 2020 Mar 12;135(11):866-870
pubmed: 31990291
Leukemia. 2013 Dec;27(12):2376-9
pubmed: 23612016
Nature. 2012 Jan 18;482(7383):53-8
pubmed: 22258507
Blood. 2020 Sep 17;136(12):1419-1432
pubmed: 32584970

Auteurs

Silvia Ramos-Campoy (S)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

Anna Puiggros (A)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

Joanna Kamaso (J)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

Sílvia Beà (S)

Hematopathology Section, Department of Pathology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Sandrine Bougeon (S)

Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, 1011 Lausanne, Switzerland.

María José Larráyoz (MJ)

Cytogenetics and Hematological Genetics Services, Department of Genetics, University of Navarra, 31008 Pamplona, Spain.

Dolors Costa (D)

Hematopathology Section, Department of Pathology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Helen Parker (H)

Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.

Gian Matteo Rigolin (GM)

Hematology Section, St. Anna University Hospital, 44121 Ferrara, Italy.

María Laura Blanco (ML)

Department of Hematology, Hospital de la Santa Creu I Sant Pau, 08041 Barcelona, Spain.

Rosa Collado (R)

Department of Hematology, Consorcio Hospital General Universitario, 46014 Valencia, Spain.

Idoya Ancín (I)

Department of Hematology and Hemotherapy, Hospital Universitario Cruces, 48903 Bilbao, Spain.

Rocío Salgado (R)

Cytogenetics Laboratory, Hematology Department, Fundación Jiménez Díaz, 28040 Madrid, Spain.

Marco A Moro-García (MA)

Laboratory Medicine Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.

Tycho Baumann (T)

Hematopathology Section, Department of Pathology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.

Eva Gimeno (E)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Applied Clinical Research in Hematological Malignances, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

Carol Moreno (C)

Department of Hematology, Hospital de la Santa Creu I Sant Pau, 08041 Barcelona, Spain.

Marta Salido (M)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

Xavier Calvo (X)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

María José Calasanz (MJ)

Cytogenetics and Hematological Genetics Services, Department of Genetics, University of Navarra, 31008 Pamplona, Spain.

Antonio Cuneo (A)

Hematology Section, St. Anna University Hospital, 44121 Ferrara, Italy.

Florence Nguyen-Khac (F)

Sorbonne University, Hematology Department, Hôpital Pitié-Salpêtrière, APHP, INSERM U1138, 75013 Paris, France.

David Oscier (D)

Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth BH7 7DW, UK.

Claudia Haferlach (C)

MLL Munich Leukemia Laboratory, 81377 Munich, Germany.

Jonathan C Strefford (JC)

Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.

Jacqueline Schoumans (J)

Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Blanca Espinet (B)

Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain.

Classifications MeSH